Skip to search formSkip to main contentSkip to account menu

Luspatercept

A soluble, recombinant fusion protein composed of a modified form of the extracellular domain of human activin receptor type IIb (ActRIIb) and linked… 
National Institutes of Health

Related topics

Related topics

1 relation

Narrower (1)

ACE-536

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Luspatercept for Lower-Risk Myelodysplasia with Ring Sideroblasts
Erythropoietin stimulating agents (ESAs) are a standard of care for patients with lower-risk myelodysplastic syndromes (MDS… 
2020
2020
Luspatercept for Transfusion-Dependent β-Thalassemia
Patients with transfusion-dependent β-thalassemia are sustained by transfusions, yet this supportive therapy adds to the risk for… 
2019
2019
Luspatercept for Beta-Thalassemia
Anemia in patients with beta-thalassemia is due to premature death of erythroblasts, resulting in expansion of the bone marrow… 
2018
2018
Anämie bei Niedrigrisiko-MDS: Luspatercept eine Option
Anämische Niedrigrisiko-MDS-Patienten, die auf eine Standardbehandlung kaum ansprechen, profitieren möglicherweise von der… 
2018
2018
„ligand trap“ als neue Therapieoption
Anämische Niedrigrisikopatienten mit myelodysplastischem Syndrom (MDS), die auf eine Standardbehandlung kaum ansprechen, pro… 
2017
2017
[Not Available].
 Die aktuelle WHO-Klassifikation hat die Nomenklatur der „refraktären Anämien“ zugunsten des Begriffs „myelodysplastisches… 
2017
2017
Myelodyplastische Syndrome – Standards und neue Entwicklungen in Diagnostik und Therapie
Was ist neu? Klassifikation Die aktuelle WHO-Klassifikation hat die Nomenklatur der „refraktären Anämien“ zugunsten des Begriffs… 
2016
2016
LUSPATERCEPT DECREASES TRANSFUSION BURDEN AND LIVER IRON CONCENTRATION IN REGULARLY TRANSFUSED ADULTS WITH BETA-THALASSEMIA
2016
2016
LUSPATERCEPT INCREASES HEMOGLOBIN, REDUCES LIVER IRON CONCENTRATION, AND IMPROVES QUALITY OF LIFE IN NON-TRANSFUSION DEPENDENT ADULTS WITH BETA-THALASSEMIA
Luspatercept Increases Hemoglobin, Reduces Liver Iron Concentration and Improves Quality of Life in Non‐Transfusion Dependent… 
2015
2015
LUSPATERCEPT (ACE-536) INCREASES HEMOGLOBIN AND DECREASES TRANSFUSION BURDEN AND LIVER IRON CONCENTRATION IN ADULTS WITH BETA-THALASSEMIA: PRELIMINARY RESULTS FROM A PHASE 2 STUDY
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)